Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118645613 | 11864561 | 3 | F | 20150922 | 20160630 | 20151223 | 20160706 | EXP | DE-TEVA-595938GER | TEVA | 7.00 | DEC | M | Y | 76.00000 | KG | 20160706 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118645613 | 11864561 | 1 | SS | Lonquex | LIPEGFILGRASTIM | 1 | LAST DOSE PRIOR TO AE: 16-SEP-2015 | ASKU | 0 | ||||||||||
| 118645613 | 11864561 | 2 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | LAST DOSE PRIOR TO AE: 15-SEP-2015 | ASKU | 77269 | 480 | MG | Q3W | ||||||
| 118645613 | 11864561 | 3 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | LAST DOSE PRIOR TO AE: 15-SEP-2015 | ASKU | 74284 | 235 | MG | |||||||
| 118645613 | 11864561 | 4 | C | AGGRENOX | ASPIRINDIPYRIDAMOLE | 1 | Oral | 400 MILLIGRAM DAILY; | 0 | 200 | MG | BID | |||||||
| 118645613 | 11864561 | 5 | C | Candesartan | CANDESARTAN | 1 | Oral | 16 MILLIGRAM DAILY; | 0 | 16 | MG | QD | |||||||
| 118645613 | 11864561 | 6 | C | Nebilet | NEBIVOLOL | 1 | Oral | 5.45 MILLIGRAM DAILY; | 0 | 5.45 | MG | QD | |||||||
| 118645613 | 11864561 | 7 | C | HCT | HYDROCHLOROTHIAZIDE | 1 | Oral | 25 MILLIGRAM DAILY; | 0 | 25 | MG | QD | |||||||
| 118645613 | 11864561 | 8 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 20 MILLIGRAM DAILY; | 0 | 20 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118645613 | 11864561 | 1 | Neutropenia |
| 118645613 | 11864561 | 2 | Bladder cancer |
| 118645613 | 11864561 | 3 | Bladder cancer |
| 118645613 | 11864561 | 4 | Embolism |
| 118645613 | 11864561 | 5 | Hypertension |
| 118645613 | 11864561 | 6 | Cardiac failure |
| 118645613 | 11864561 | 8 | Hypercholesterolaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118645613 | 11864561 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118645613 | 11864561 | Anaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118645613 | 11864561 | 1 | 20150916 | 20160114 | 0 | |
| 118645613 | 11864561 | 2 | 20150915 | 20160115 | 0 | |
| 118645613 | 11864561 | 3 | 20150915 | 20160115 | 0 |